Erasca reports 44% confirmed response in Phase 1 pancreatic cancer trial, shares dip 5%

Erasca Inc. disclosed updated Phase 1 data for its pan‑RAS drug ERAS‑0015, showing a 44% confirmed objective response rate in 25 previously treated pancreatic cancer patients receiving 32 mg daily. The response was higher in the KRAS G12D/G12V subgroup at 69%. The company said the results accelerate plans for a first‑line Phase 3 trial in the first half of 2027. The announcement coincided with a 5% drop in ERAS shares.

The market reaction was a 5% decline in ERAS stock on the day of the release. Investors will watch whether the early response rates hold in larger, later‑stage trials scheduled for 2027.

  • 1ERAS‑0015 achieved a 44% confirmed objective response rate in 25 pancreatic cancer patients.
  • 2In the KRAS G12D/G12V subgroup (13 patients) the confirmed response rate was 69%.
  • 3The trial population was heavily pretreated, with 84% receiving the drug as third‑line or later therapy.
  • 4ERAS shares fell 5% after the data release.
  • 5Erasca plans to start a registration‑enabling Phase 3 pancreatic cancer trial in the first half of 2027.
  • 6The Phase 1 trial (AURORAS‑1) began in June 2025 and has enrolled 148 patients with RAS‑mutated tumors to date.

Sources